TY - JOUR
T1 - Proceedings of the third global workshop on chronic myeloid leukemia
AU - Saglio, Giuseppe
AU - Kantarjian, Hagop
AU - Holyoake, Tessa
AU - Ranganathan, Aarati
AU - Cortés, Jorge E.
N1 - Funding Information:
The workshop was supported by an educational grant from Bristol-Myers Squibb Company.
Funding Information:
Giuseppe Saglio has served as a consultant or been on an advisory board/research panel, and has served on a Speaker's Bureau for Bristol-Myers Squibb Company and Novartis Pharmaceuticals Corporation. Jorge E. Cortés has received research funding from, served as a consultant for, and been on a Speaker's Bureau for ARIAD Pharmaceuticals, Inc., Bristol-Myers Squibb Company, ChemGenex Pharmaceuticals, and Novartis Pharmaceuticals Corporation. The remaining authors have no relevant relationships to disclose.
PY - 2010/12
Y1 - 2010/12
N2 - Tyrosine kinase inhibitor (TKI) therapy has resulted in unprecedented responses and survival rates in Philadelphia chromosome positive chronic myelogenous leukemia (CML) that are durable for years. However, a third of patients either fail to respond or respond suboptimally to imatinib therapy, while some others are intolerant to imatinib. Increased understanding of the molecular basis of imatinib resistance has led to rational development of second-generation TKIs as effective second-line treatment options for imatinib-resistant patients. However, persistence of minimal residual disease (MRD) and development of resistance against TKI therapy are proving to be significant challenges. Treatment options are evolving for patients with CML and the promising results with several novel agents showing activity in CML, including in patients with the T315I mutation, are encouraging advancements in the field. Recently, a panel of global experts in CML deliberated on the imminent approval of second-generation TKIs in the frontline setting, ways to improve on frontline therapy, integration of new agents in current treatment algorithms, and design of future clinical trials; the proceedings of the discussion are summarized in this article.
AB - Tyrosine kinase inhibitor (TKI) therapy has resulted in unprecedented responses and survival rates in Philadelphia chromosome positive chronic myelogenous leukemia (CML) that are durable for years. However, a third of patients either fail to respond or respond suboptimally to imatinib therapy, while some others are intolerant to imatinib. Increased understanding of the molecular basis of imatinib resistance has led to rational development of second-generation TKIs as effective second-line treatment options for imatinib-resistant patients. However, persistence of minimal residual disease (MRD) and development of resistance against TKI therapy are proving to be significant challenges. Treatment options are evolving for patients with CML and the promising results with several novel agents showing activity in CML, including in patients with the T315I mutation, are encouraging advancements in the field. Recently, a panel of global experts in CML deliberated on the imminent approval of second-generation TKIs in the frontline setting, ways to improve on frontline therapy, integration of new agents in current treatment algorithms, and design of future clinical trials; the proceedings of the discussion are summarized in this article.
KW - Bcr-abl
KW - Chronic myelogenous leukemia
KW - Dasatinib
KW - Imatinib
KW - T315I mutation
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=79952961509&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952961509&partnerID=8YFLogxK
U2 - 10.3816/CLML.2010.n.077
DO - 10.3816/CLML.2010.n.077
M3 - Article
C2 - 21156461
AN - SCOPUS:79952961509
SN - 2152-2650
VL - 10
SP - 443
EP - 451
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 6
ER -